股价表现：截至2026年02月13日，正业生物收盘价为0.96美元，单日跌幅4.75%。近7日（02月08日至02 月14日）区间涨跌幅为14.52%（以02月07日收盘价0.84美元为起始点），最高价触及1.19美元（02月10 日），最低价下探0.77美元（02月09日），区间振幅达50.24%。 交易情况：近7日成交量和成交额较前期放大，但整体流动性较低，02月13日换手率仅为0.03%。同期 美股大盘指数震荡，纳斯达克指数近五日跌幅2.10%，制药板块涨跌幅为1.06%。 行业关联：公司主营兽用疫苗（尤其猪疫苗），近期生猪养殖行业数据发布频繁（如傲农生物1月生猪 销售量同比增长35.36%），可能间接影响市场情绪。 来源：经济观察网 经济观察网 正业生物近7个交易日股价波动显著，区间振幅较大。公司期间通过官方渠道定期发布生猪 价格快报，更新行业数据，但未披露重大业务进展或事件。这些信息主要为行业动态更新，对股价直接 影响有限。 股票近期走势 以上内容基于公开资料整理，不构成投资建议。 ...

Investment Rating - The report maintains an "Overweight" rating for the agricultural, forestry, animal husbandry, and fishery sector, indicating a positive outlook for the industry compared to the overall market performance [1][4]. Core Insights - The total net profit for the tracked companies in the agricultural, forestry, animal husbandry, and fishery sector is projected to be CNY 30.949 billion for 2025, reflecting a year-on-year decrease of 20%. The top three sub-sectors by profit growth are animal health (+76%), planting industry (+54%), and pet food (+3%) [3][4]. - The report highlights significant performance disparities among different sectors, with the animal husbandry sector facing challenges due to oversupply and declining prices, particularly in pig farming, where the average price of pigs dropped by 29.9% year-on-year [3][5]. - The pet food sector shows resilience in domestic markets despite a slowdown in overseas growth, with a projected online sales growth of 10.2% in 2025 [3][4]. Summary by Relevant Sections Animal Husbandry - The pig farming sector is expected to see a net profit of CNY 20.908 billion in 2025, down 26% year-on-year, with significant losses reported in Q4 [5][8]. - The chicken farming sector remains profitable, with white chicken prices stable and yellow chicken prices showing a 9.5% increase year-on-year [3][4]. Pet Food - Domestic pet food sales are projected to grow, with major companies like Guobao Pet and Zhongchong Co. expected to report net profits of CNY 0.678 billion and CNY 0.433 billion, respectively [3][4]. Planting Industry - The report notes a recovery in edible mushroom prices, with a projected net profit increase of 154% for Zhongxing Junye in 2025 [3][4]. - Blueberry prices have slightly decreased, but companies are expected to maintain profitability through volume sales [3][4]. Animal Health - The animal health sector is projected to see a net profit increase of 76%, driven by new product launches and increased demand for veterinary vaccines [3][4]. Seed Industry - The seed industry is facing challenges with low grain prices, leading to a mixed performance among companies, with Dabeinong expected to report a significant loss [3][4].

Core Insights - The event themed "Creating a New Engine for the Development of the Biological Economy in Heilongjiang" highlighted the achievements of Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. (referred to as "Harbin Vaccine") as a leading enterprise in veterinary biological products in Heilongjiang for 63 years, showcasing the synergy of resource endowment, technological reserves, and policy support in the region's biological economy [2] Group 1 - Harbin Vaccine has established a solid innovation foundation through its SPF experimental animal production base and deep collaborations with various research institutions, leading to significant growth in recent years [2] - The company has received 10 new veterinary drug certificates and generated nearly 10 million yuan in technology transfer income, with new product sales exceeding 20 million yuan, covering over 80% of the national market [2] Group 2 - Three key recommendations were proposed to address industry pain points: forming a provincial innovation consortium for veterinary biological products to integrate resources from universities, research institutions, and leading enterprises; establishing a risk warning mechanism for the supply chain; and creating a local supply-demand matching platform to promote the application of local vaccine products in large-scale breeding enterprises [3]

Investment Rating - The report maintains a "Recommended" rating for the agricultural, forestry, animal husbandry, and fishery industry [1] Core Viewpoints - The report emphasizes the ongoing adjustment in the pig industry, highlighting the potential for value reassessment due to production capacity control and low-cost performance realization [3][16] - The poultry sector is expected to see improvements in fundamentals, with a focus on the white feather chicken breeding segment and price trends [4][29] - The animal health sector is witnessing a competitive landscape improvement and technological innovation, with several new products receiving clinical approval [5][37] - The pet economy is thriving, with domestic brands rapidly emerging, indicating sustained profitability improvements in the sector [9][59] Summary by Sections Pig Industry - Continuous deepening of pig price control measures is noted, with a focus on maintaining prices within a reasonable range [3][16] - Current average pig price is 13.15 yuan/kg, with a slight weekly decline [15] - Recommended companies include Muyuan Foods and Wens Foodstuffs, with ongoing recommendations for Juxing Agriculture and Shennong Group [3][16] Poultry Industry - The white feather chicken breeding segment shows potential for improvement, with significant updates in breeding stock [4][29] - Current prices for white feather chicken and related products are stable, with slight fluctuations noted [27][28] Animal Health Industry - The competitive landscape is improving, with notable profit differentiation among leading companies [5][36] - Several new vaccines have received clinical approval, marking significant advancements in the sector [5][37] Planting Industry - Prices for corn and soybean meal have shown a week-on-week decline, with ongoing commercialization of genetically modified seeds benefiting early adopters [7][42] Feed Industry - Feed prices are experiencing fluctuations, with a noted increase in production volume [8][48] - Recommended companies include Haida Group, with a focus on rising industry concentration [8][49] Pet Industry - The pet market is projected to reach 300.2 billion yuan in 2024, with a notable increase in consumer spending on pets [9][58] - Recommended companies in the pet food sector include Guobao Pet and Zhongchong Co., with a focus on the growing pet medical segment [9][59]

Company Overview - Jinhe Biology Co., Ltd. is located in Inner Mongolia and was established on March 14, 1990, with its listing date on July 13, 2012 [2] - The company specializes in the production, sales, research, and service of animal health products, with a revenue composition of 61.83% from veterinary chemical drugs, 19.76% from starch and related products, 11.12% from veterinary vaccines, 4.97% from environmental services, and 2.15% from other sources [2] Financial Performance - For the first half of 2025, Jinhe Biology achieved a revenue of 1.39 billion yuan, representing a year-on-year growth of 30.45%, and a net profit attributable to shareholders of 138 million yuan, up 51.52% year-on-year [2] - The company has distributed a total of 877 million yuan in dividends since its A-share listing, with 227 million yuan distributed over the past three years [3] Stock Performance - As of September 16, Jinhe Biology's stock price was 7.05 yuan per share, with a market capitalization of 5.44 billion yuan [1] - The stock has increased by 61.22% year-to-date, with a recent 5-day increase of 1.29%, a 20-day decrease of 5.87%, and a 60-day increase of 12.44% [1] - The company has appeared on the trading leaderboard six times this year, with the most recent occurrence on April 16, where it recorded a net buy of -28.30 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 104.38% to 64,500, while the average circulating shares per person decreased by 51.07% to 11,547 shares [2] - Among the top ten circulating shareholders, Guotai Zhongzheng Livestock Breeding ETF is the third-largest shareholder, holding 7.66 million shares as a new investor [3]

Group 1 - The core viewpoint of the article is that Xianfeng Holdings (002141.SZ) clarifies that its products are primarily veterinary vaccines and not human vaccines, indicating that the company does not have the production and research conditions for human vaccines [1]

Core Viewpoint - Jinhe Biology demonstrated strong financial performance in the first half of 2025, with significant revenue and profit growth, particularly in the veterinary chemical drug sector [2][11]. Financial Overview - Total revenue reached 1.39 billion yuan, a year-on-year increase of 30.45% [2]. - Net profit attributable to shareholders was 138 million yuan, up 51.52% year-on-year [2]. - The second quarter saw total revenue of 765 million yuan, a 40.05% increase, and net profit of 86.8 million yuan, growing by 89.2% [2]. Profitability - The company's gross margin improved to 34.55%, an increase of 3.76% year-on-year [3]. - Net profit margin rose to 9.92%, up 16.73% year-on-year, indicating effective cost control and enhanced product value [3]. Costs and Expenses - Total operating expenses amounted to 279 million yuan, accounting for 20.03% of revenue, an increase of 2.32% year-on-year [4]. - Management expenses grew by 36.2%, primarily due to salary increases, depreciation from completed projects, and increased stock incentive costs [4]. - Financial expenses rose by 46.74%, attributed to interest expenses from completed projects and reduced foreign exchange gains in the previous year [4]. Cash Flow and Debt Situation - Cash and cash equivalents decreased to 625 million yuan, down 5.21% year-on-year [5]. - Operating cash flow per share was 0.17 yuan, a decline of 20.08% [5]. - Net cash flow from financing activities dropped by 95.88%, and net increase in cash and cash equivalents fell by 89.9% [5]. - Interest-bearing liabilities increased to 2.528 billion yuan, up 0.72% year-on-year, with an interest-bearing asset-liability ratio of 41.41% [5]. Accounts Receivable - Accounts receivable stood at 590 million yuan, a year-on-year increase of 22.22%, with a ratio to profit of 589.11%, indicating a need to monitor collection [6]. Main Business Analysis - The veterinary chemical drug segment generated 860 million yuan, accounting for 61.83% of total revenue, with a gross margin of 38.13% [7]. - Revenue from starch and related products was 275 million yuan, making up 19.76% of total revenue, with a gross margin of 11.15% [7]. - Veterinary vaccine revenue reached 155 million yuan, representing 11.12% of total revenue, with a gross margin of 54.87% [7]. - Environmental services contributed 69.13 million yuan, accounting for 4.97% of total revenue, with a gross margin of 44.25% [7]. Regional Distribution - Domestic sales revenue was 802 million yuan, accounting for 57.67% of total revenue, with a gross margin of 26.59% [8]. - International sales revenue reached 588 million yuan, making up 42.33% of total revenue, with a gross margin of 45.40% [8]. Development Strategy - The company focuses on its core animal health business, with a dual-driven model of veterinary pharmaceuticals and vaccines, supported by environmental and agricultural processing sectors [9]. - The completion of the sixth phase project added 60,000 tons of production capacity for key products, enhancing competitiveness through cost reduction and improved fermentation indices [9]. - The veterinary vaccine business has rapidly established a comprehensive industry layout through self-built and acquired production bases and R&D centers [9].

Investment Rating - The report rates the agricultural, forestry, animal husbandry, and fishery industry as "Overweight" due to expected overall profit improvement in the sector [3][4]. Core Insights - The report highlights that the profitability of pig farming is expected to improve, with a stable pig price and a significant increase in average profit per head for self-bred pigs [4]. - Poultry farming shows a mixed outlook, with white chicken prices bottoming out and yellow chicken profitability declining, while egg-laying chicks continue to experience high demand [4]. - The pet food sector is projected to maintain high growth, with leading companies showing strong online sales growth, despite a decline in exports to the U.S. due to tariffs [4]. - Animal health is recovering, with increased demand for vaccines and improved sales of veterinary preparations [4]. - The seed industry faces challenges with declining corn prices and increased competition, leading to pressure on the performance of leading seed companies [4]. Summary by Sections Pig Farming - The average price of pigs in H1 2025 is expected to be 14.80 CNY/kg, a decrease of 4.2% year-on-year, while the average profit for self-bred pigs is projected at 69.04 CNY/head, recovering from a loss of 24.82 CNY/head in H1 2024 [4]. Poultry Farming - White chicken prices are under pressure due to oversupply, with the average price for commodity broiler chicks at 2.4 CNY/bird, down 21% year-on-year. Yellow chicken prices are also declining, with the average price for Qingjiao chicken at 8.9 CNY/kg, down 19% year-on-year [4]. Pet Food - The domestic pet food market is experiencing a growth rate of 17% in online GMV for the first five months of 2025, compared to 14% in the same period of 2024. Leading companies like Guibao Pet and Zhongchong Co. show growth rates of 51% and 26%, respectively [4]. Animal Health - The demand for veterinary vaccines has increased, with a 15.8% year-on-year rise in vaccine approvals in the first five months of 2025. Prices for veterinary preparations like Tylosin and Tiamulin have increased by 39.8% and 9.3%, respectively [4]. Seed Industry - The corn seed market is under pressure due to falling corn prices and high competition, leading to a decline in seed prices and performance expectations for leading seed companies [4].

Core Viewpoint - The company has faced significant financial challenges, reporting a net loss of 1.13 billion yuan for 2024, marking two consecutive years of substantial losses. The company is implementing measures to enhance its operational efficiency and profitability, particularly through its new copper-clad laminate business [1][3][6]. Financial Performance - The company's operating revenue for 2024 was 418 million yuan, with a net profit attributable to shareholders of -1.13 billion yuan. The revenue for the first three quarters of 2024 was only 46 million yuan, while the fourth quarter saw a significant increase to 314 million yuan due to the launch of the copper-clad laminate business [1][6]. - The first quarter of 2025 showed a slight improvement, with main business revenue of 287.23 million yuan and a gross profit margin of 6.45% [6][7]. Business Strategy and Measures - The company plans to deepen its focus on the electronic information industry and expand into AI and new energy applications. Specific strategies include cost reduction, optimizing material procurement, and enhancing production efficiency [3][4][5]. - The copper-clad laminate business aims for comprehensive cost reduction and efficiency improvement, with a focus on optimizing manufacturing costs and enhancing product quality [3][4][5]. Customer and Market Analysis - The company has established a stable business model for its new copper-clad laminate operations, with a registered capital of 50 million yuan and significant investment in production capacity [8][9]. - The top five customers for the copper-clad laminate business accounted for 55.35% of sales, indicating a moderate level of customer concentration, which has decreased to 47.48% in the first quarter of 2025, suggesting improved customer diversification [10][12]. Operational Challenges - The company has faced challenges related to continuous losses, with significant impairments and operational losses attributed to various factors, including the performance of its new materials business [1][3]. - The company has implemented measures to address these challenges, including enhancing internal controls and improving financial management practices [19][20]. Future Outlook - The company is optimistic about the long-term demand for copper-clad laminates, driven by growth in downstream industries such as aerospace, consumer electronics, and automotive sectors [9][12]. - The company has committed over 400 million yuan to the copper-clad laminate business and is confident in its ability to sustain operations and improve profitability through strategic initiatives [9][10].

Investment Rating - The report maintains a "Positive" outlook on the agriculture, forestry, animal husbandry, and fishery sector, indicating it is expected to outperform the overall market [4][5][52]. Core Insights - The report highlights the strong performance of the pig farming sector, with expectations for a re-evaluation of pig prices due to ongoing market dynamics. It emphasizes the importance of quality pig farming enterprises and suggests focusing on the profitability of breeding support and pet food sectors [4][5]. - During the "618" shopping festival, the pet food industry showed resilience, with leading brands performing well. The report suggests that the performance of top companies may exceed expectations throughout the year [4][5]. - The report notes that pig prices have consistently outperformed market expectations since the beginning of 2025, with futures prices remaining lower than spot prices. It anticipates a slow recovery in production capacity and highlights the potential for profit realization in low-cost pig farming [4][5]. Summary by Sections Market Performance - The Shenwan Agriculture, Forestry, Animal Husbandry, and Fishery Index fell by 3.1%, while the CSI 300 Index decreased by 0.5%. The top five gainers included Bangji Technology (up 24.7%) and Chenguang Biotech (up 13.4%), while the top five losers included Andeli (down 18.7%) and Zhongchong Co. (down 13.4%) [4][5][12]. Pig Farming - As of June 22, the average selling price of external three yuan pigs was 14.29 yuan/kg, with a week-on-week increase of 1.2%. The report indicates that the average weight of market pigs decreased to 128.28 kg, down 0.54 kg from the previous week. The report suggests that the expectations of "reducing weight, stabilizing production capacity, and limiting breeding" may lead to a re-evaluation of pig prices in the second half of the year [4][5]. Poultry Farming - The report notes a significant drop in chick prices, with the average price of white feather broiler chicks at 1.72 yuan/chick, down 29.2% week-on-week. The average price of white feather broilers remained stable at 3.52 yuan/kg, with a slight decrease of 1.7% week-on-week [4][5]. Pet Food - The report emphasizes the importance of monitoring the sales performance of pet food during the "618" shopping festival, with a year-on-year increase of 15% in e-commerce sales. The total sales for pet food reached 7.5 billion yuan, up from 5.5 billion yuan in the previous year, indicating a year-on-year growth of 36% [4][5]. Animal Health - The report highlights the recovery in vaccine sales, with a year-on-year increase of 23.02% in the number of veterinary vaccine batches issued in Q1 2025. It suggests that the profitability of breeding enterprises will drive the demand for vaccines and other products [4][5].